Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-09-09), Legend Biotech's 14-Day RSI is 42.98.
The industry rank for Legend Biotech's 14-Day RSI or its related term are showing as below:
STU:9LB's 14-Day RSI is ranked worse than 56.27% of 1420
companies
in the Biotechnology industry
Industry Median: 48.76
vs STU:9LB: 42.98
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Legend Biotech 14-Day RSI Related Terms
STU:9LB vs IDYA, DNLI, TNGX: 14-Day RSI Comparison
For the Biotechnology subindustry, Legend Biotech's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Legend Biotech 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Legend Biotech's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Legend Biotech's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Legend Biotech (STU:9LB) has a 14-Day RSI of 42.98 as of Sep. 09, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Legend Biotech and its competitors. According to the industry distribution chart, Legend Biotech ranks #799 out of 1420 companies in the Biotechnology industry, placing it in the top 56.3%.
Is Legend Biotech's 14-Day RSI too high?
Legend Biotech's current 14-Day RSI is 42.98. The Biotechnology industry median 14-Day RSI is 48.76. Legend Biotech's value of 42.98 is 11.9% below this industry median. Based on the distribution chart, Legend Biotech ranks #799 out of 1420 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Legend Biotech has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's 14-Day RSI compare to IDYA and DNLI?
According to the Biotechnology industry distribution chart, Legend Biotech ranks #799 out of 1420 companies for 14-Day RSI. This places Legend Biotech in the lower half of its industry. The industry median 14-Day RSI is 48.76. Legend Biotech's value of 42.98 is 11.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.76, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Legend Biotech's current 14-Day RSI of 42.98 is 11.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Legend Biotech and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Legend Biotech's current 14-Day RSI is 42.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (STU:9LB) is currently considered Significantly Undervalued. The stock's GF Value™ is €68.01, compared to a current price of €17.50 — trading 74.3% below its estimated fair value. The current 14-Day RSI is 42.98 and 11.9% below the Biotechnology industry median of 48.76. Legend Biotech's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Legend Biotech (STU:9LB), the current 14-Day RSI is 42.98 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Legend Biotech (STU:9LB) Overvalued in 2026?
Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued.
The current stock price of €17.50 is trading 74.3% below its estimated GF Value™ of €68.01.
GuruFocus considers Legend Biotech to be Significantly Undervalued.
Key valuation signals for STU:9LB:
14-Day RSI: 42.98
GF Value™: €68.01 vs. price of €17.50 (74.3% below fair value)
Industry Position: 11.9% below the Biotechnology median (#799 of 1420)
No single metric tells the full story. See the STU:9LB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
69GF Score
Get the complete analysis for STU:9LB
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:9LB has been successfully added to your 
